Although the number of subjects was small, our clinical trial findings suggest that HFLD significantly increased circulating SOD, CAT, and GSH/GSSG ratio and decreased MDA, TNF-α and IL-6 levels, indicating that HFLD may treat AF by alleviating oxidative stress and inflammation. This evidence concerns the gene SOD1 and atrial fibrillation.